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1. Introduction 
The characteristic neuropathological markers of PD are the presence of Lewy bodies, 
containing modified -synuclein amongst other proteins, in the surviving neurons, and the 
degeneration of neuromelanin-containing dopaminergic neurons in the substania nigra par 
compacta region of the brain. In addition, the progressive nature of PD is characterised by 
chronic innate inflammation with microglial activation, as well as astrogliosis and 
lymphocytic infiltration, which are implicated in both the initiation and progression of PD 
(Qin et al., 2007). Activation of microglial cells will increase the activity of NADPH-oxidase, 
(with the release of reactive oxygen and nitrogen species). In addition, mitochondrial 
dysfunction as well as cytotoxicity, (via glutamate release) will occur, which will contribute 
to the pro-inflammatory state. Abnormal proteasome function in PD contributes to the build 
up of -synuclein aggregates within specific brain which will contribute to inflammation 
through the activation of microglia (reviewed in Crichton and Ward, 2006). Alterations in 
the innate and adaptive immune systems are reported in PD and will be reviewed in this 
chapter. Furthermore, considerable evidence over the past few years has indicated that there 
is a generalised inflammatory response in PD, that is present in both the brain and the 
periphery. Therapeutic intervention to retard such inflammation may reduce the 
progression of neurodegeneration in PD. 
2. Immune system overview 
The immune system is an intricate network of specialised tissues, which protects the host from 
infection. It can be divided into two interactive systems, innate and adaptive immunity. 
2.1 Innate immune system and inflammation 
Innate immunity is characterised by the immune system's ability to rapidly mobilize a 
response to an invading pathogen, toxin, or allergen, by distinguishing self from non-self. 
Toll like receptors, (TLRs), as well as nucleotide binding and oligomerization domain, 
(NOD-like receptors) and the cytoplasmic helicase retinoic acid inducible gene protein 1, 
(RIG-I-like receptors), are located on the phagocytic cell membranes, (e.g. macrophages and 
microglia) (Figure 1). These play a fundamental role in innate recognition of neuronal 
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damage, by sensing pattern recognition receptors, (PRRs), on endogenous danger-associated 
molecules e.g. NOD-like receptors, (Reviewed in Ward et al., 2010). Activation of 
inflammatory gene transcription and post-translational processing will then occur. Innate 
immunity is present at birth, the effector cells being mostly myeloid cells, neutrophils, 
monocytes and macrophages, which on activation, release immunoactive substances such as 
cytokines, neurotrophic factors, chemokines, reactive oxygen and nitrogen species. In 
addition, a number of inhibitory pathways are induced during this pro-inflammatory stage, 
which ensure that the elevation in cytokine response does not overwhelm the host. 
 
 
Fig. 1. Danger signals from the external environment or the cytosol are transduced through 
adapter protein pathways to the nucleus. TLR4 plays a major role in the activation of the 
immune responses. 
Microglia, a subset of glial cells (the other two being oligodendrocytes and astrocytes), are 
regarded as the resident immuno-competent effector cells of the innate immunity in the 
brain. (Figure 2). In normal circumstances, they have two important roles; a) as surveillance 
cells, to regulate and supervise the removal of cell debris after neuronal death, after which 
the micoglia will return to their quiescent state, and b) controlling apoptosis. Microglia 
originate either from circulating monocytes or precursor cells that colonise the nervous 
system primarily during embryonic and foetal periods of development (reviewed by Chan 
et al., 2007). Microglia are considered to be primary mediators of neuroinflammation and, as 
such, have a vast repertoire of PPR as well as TLRs and phagocytic receptors. In the healthy 
adult brain they exist in a non-activated state, equipped with receptors for 
neurotransmitters, neuropeptides, hormones and immune signals. Activated microglia show 
a phenotypical repertoire which include the synthesis of MHC class 1 and II antigen  
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Fig. 2. Activated microglia showing highly branched processes in the ramified state. 
 
 
Fig. 3. Activated microglia showing NADPH oxidase activation and the subsequent 
generation of superoxide and nitric oxide. 
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presenting proteins, release cytokines such as IL-1, IL-2, IL-6. TGF-1, CREB, the synthesis 
of complement components and their receptors, together with the mitogens M-CSF, GM-
CSF and IL-3, Table 1. Cytokines are low molecular weight proteins, which modulate 
microglial activation by binding to their receptors, which are expressed on microglia. Pro-
inflammatory cytokines e.g. IL-6, have the ability to elicit a sustained immune response 
while anti-inflammatory cytokines e.g. IL-10, down-regulate the immune response by 
binding to appropriate receptors on microglia and initiating an autocrine signalling process. 
Cytokine effects on the CNS function include growth promotion, inhibition and 
proliferation of astrocytes and oligodendrocytes, modulation of neurotransmitter release, 
long term potentiation which is linked to memory formation, and anxiety.  Microglia also 
show a strong respiratory burst capacity, via NADPH oxidase, as well as the ability to 
release cytotoxic cytokines such as TNF, and can produce both reactive nitrogen and 
oxygen species, (Figure 3). In normal circumstances, the inflammatory response would be 
rapid, decisive and then decline. In PD it is hypothesised that microglia priming may alter 
brain homeostasis. Furthermore, Perry (2004) proposed that chronic exposure to pro-
inflammatory signals from systemic infection during an individual’s lifetime, might 
promote an exaggerated microglial response that could contribute to neuronal deterioration, 
instead of facilitating a protective homeostatic response.  
 
 
Table 1. Changes in mRNA expression of iron genes involved in iron homeostasis in the 
substantia nigra and cortex of PD patients compared with controls in post mortem tissue 
3. Inflammation in PD brain-innate immune response 
In early studies, McGeer et al., (1998) presented evidence for neuro-inflammation in the 
substantia nigra, (SNc) of PD patients with high numbers of activated microglia particularly 
in the vicinity of the degenerating neurons. This has been substantiated in many other 
studies (Dauer and Przedborski 2003; Bartels and Leenders 2007; Gao and Hong 2008). 
Furthermore increased levels of pro-inflammatory cytokines, e.g. TNF IL1, IL-2 and IL-6, 
as well as 2 microglobulin, epidermal growth factor, transforming growth factor, 
cyclooxygenase 2 and reactive oxygen and nitrogen species are evident, post mortem, in PD 
brains (reviewed by Qian et al., 2010), as well as the cerebrospinal fluid (Hald and Lotharius, 
2005).  More recently, single positron emission tomography (PET) has shown that levels of 
www.intechopen.com
 Parkinson’s Disease and the Immune System 
 
123 
[11C] (R)-PK11195, an isoquinoline carboxamide which binds selectively to the peripheral 
benzodiazepine receptor (PBR), (also known as the mitochondrial 18 kDa translocator 
protein or TSPO) a selective marker for activated microglia is significantly higher in PD 
patients than control subjects and correlated with dopaminergic terminal loss, as assayed by 
[11C] CFT BP (Ouchi et al., 2009). Whether the activation of microglia is an initial event in 
the development of PD or as a consequence of the degeneration of dopaminiergic neurons 
remains unclear. However it would seem that there is a self perpetuating cycle whereby 
microglia remain continuously activated and hence represent a suitable drug target. A 
variety of factors will contribute to this inflammatory process:  
Release of ATP from damaged neurons and/or astrocytes will initiate a rapid microglial 
response towards the site of injury (Davalos et al., 2005), Figure 4. In culture it has been 
shown that extracellular ATP will induce rapid microglia ruffling and whole cell migration, 
which is mediated via G-protein-coupled P2Y receptors (Honda et al., 2001). Extracellular 
ATP is also released from CD4+ helper T cells, upon stimulation of the T cell receptor. This 
also plays a crucial role in protracting the TCR-initiated activity of MAPK and secretion of 
IL-2, thus determining productive T cell activation. Recent published research indicated that 
ATP also inhibits the generation and function of regulatory T cells via the activation of 
purinergic P2X receptors (Shenk et al., 2011). Release of ATP from damaged neurons and/or 
astrocytes will initiate a rapid changes in astrocyte function. Activated astrocytes are present 
in the regions of the degenerating SNc, which will contribute to the elevated cytokine  
 
 
Fig. 4. Release of ATP from damaged neurons (adapted from Davalos et al., 2005). 
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content in this region (Forno et al., 1992). Some studies have identified a loss of astrocytes in 
the substatia nigra pars compacta of PD brains by comparison to controls (Damier et al., 
1993). Such losses of astrocytes may imply a loss of neurotrophic support for neurons. 
However this has not been confirmed in other studies of PD brains (Mirza et al., 2000). 
Abnormal accumulation and aggregation of -synuclein occurs in PD. The amyloid fibril of  -
synuclein will aggregate to form Lewy bodies, Figure 5. Such Lewy bodies will attract 
activated microglia (McGeer et al., 1988). Iron, which is increased in PD, will enhance 
intracellular aggregation of -synuclein which leads to the formation of advanced glycation 
end products. In addition, there maybe an interaction between  -synuclein and Fe2+ to liberate 
hydroxy radicals, thereby contributing to the oxidative stress (Crichton & Ward, 2006).  
Matrix metalloproteins, (MMPs) are proteolytic enzymes which activate microglia.  
Neuronal cells, in particular in dopaminergic neurons, release MMP-3 which is increased in 
response to various forms of cellular stress (Kim and Hwang, 2011). Thus will activate 
microglial cells with the production of TNFand IL-1 as well as superoxide. The molecular 
mechanisms involved are unknown but may involve cleavage of surface proteins on 
microglial cells such as receptors, cell-cell interaction proteins, cytokines and chemokines 
(reviewed by Kim and Hwang 2011). 
Neuromelanin, a granular dark brown pigment, is produced in catecholaminergic neurons 
of the SNc and locus coeruleus and is possibly the product of reactions between oxidised 
catechols with a variety of nucleophiles, including thiols from glutathione and proteins 
(Götz et al., 2004). The function of neuromelanin in the pigmented neurons is unknown but 
it could play a protective role via attenuation of free radical damage by binding transition 
metals, particularly iron. In normal individuals, the neuromelanin-iron complex is found in  
 
 
Fig. 5. Possible action of MMP-3 in neurodegeneration (adapted from Kim and Hwang, 2011) 
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both the SNc and locus coeruleus and increases linearly with age in the SNc. Whether the 
ability of the neurones to synthesis neuromelanin is impaired in PD patients is unknown, 
since it has been reported in some studies that the absolute concentration of nigral 
neuromelanin in individual neurons is less than 50% in PD with respect to age matched 
controls. However it is considered that when neuromelanin is released from the damaged 
neurons this will trigger microgliosis, microglial chemotaxis and microglial activation in PD 
with the subsequent release of neurotoxic mediators (reviewed in Crichton and Ward, 2006). 
3.1 Stress 
Stress will also have a major effect on microglial cells. Glucocorticoids are the major effector 
hormones of the stress system and act by binding to intracellular receptors within the cell, 
which are then translocated to the nucleus and act as regulators of gene expression. 
Generally female mammals show more robust behavioural and somatic responses to stress 
as well as more potent and inflammatory reactions than males (Chrousos, 2010). Stress 
hormones target glial cells, as well as neurons. (Jauregui-Huerta et al., 2010). Evidence that 
stress may contribute to the development of PD is unclear. However chronic stress will 
directly activate microglia as well as facilitating neuronal degeneration, which would 
activate microglia. Although psychological stress and glucocorticoids are reported to 
suppress immune function, (e.g. produce anti-inflammatory cytokines and reduce toxic 
radicals), possibly via glucocorticoid receptors on dopaminergic neurons, (Barcia et al., 
2009), recent studies have indicated that glucocorticoids can enhance immune function in 
the brain (Reviewed by Jauregui-Huerta et al.,2010). This may be dependent upon the levels 
of glucocorticoids; i.e. high levels are pro-inflammatory while basal or low stress levels have 
traditional anti-inflammatory action.  Such results may be important in that such stress-
induced microglial activation may be involved in the progression of neurodegenerative 
diseases. Of the 13 epidemiological studies where the effect of stress has been studied as a 
possible contributory cause of PD, twelve of these studies were positive. 
Serum factors, thrombin and immunoglobulins can initiate activation through protease-
activated receptor 1 and Fc receptors, possibly after their passage across the BBB. 
4. Polymorphisms of pro-and anti-inflammatory genes 
Other contributory factors to the inflammation in PD could be functional DNA 
polymorphisms in some of the pro-inflammatory and anti-inflammatory cytokines which 
include TNF- and IL-1 genes (Wahner et al., 2007), IL-18 607C/A polymorphism and allele 1 
(C) of IL-1 (-511) (Arman et al., 2010), all of which are associated with an increased risk of PD 
in different populations. In contrast, the 2/2 (T/T) genotype of IL-1 (-511) may protect 
individuals from PD (Arman et al., 2010). Genetic variations may also be present in the HLA 
(human leukocyte antigen) region, where there are numerous immune related genes, which 
would increase the risk of PD (Hamza et al., 2010: Wahner et al., 2007). The importance of 
TLR4  polymorphisms in modulating the inflammatory responses has been identified. 
5. Apoptosis 
Neurons and glia express cellular death signalling pathways which include CD95 (Fas) 
/CD95L, (FasL), TNF-TNFR-1, tumor necrosis factor- tumor necrosis factor receptor 1, and 
TNF-related apoptosis-inducing ligand (TRAIL), with which they are able to trigger apoptosis 
in T cells and other infiltrating cells (Griffiths et al., 2009). Glia also express pentraxins and 
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complement proteins. C1q, C3b and iC3b. . Hence, the rapid destruction of infiltrating T cells 
as well as injured neurons can be achieved by apoptosis in normal circumstances. Since 
apoptotic cells contain potentially neurotoxic proteins and cytokines their presence must be 
rapidly detected and cleared to prevent tissue damage. Such cells will express cell surface 
apoptotic cell-associated molecule patterns (ACAMPs) (that are comparable to PRPs), thereby 
identifying these cells for rapid removal from CNS to protect further damage. Failure to clear 
these apoptotic cells, which occurs in PD, will result in their accumulation within specific CNS 
tissues. Secondary necrosis of these cells will result in the release of their toxic contents thus 
enhancing tissue damage. Both CD47 and CD200 are expressed on microglia and are up-
regulated during apoptosis, thereby inhibiting pro-inflammatory microglial cytokine 
expression. Apoptosis is a highly orchestrated form of cell death when a number of caspases 
are activated in a sequential manner. Inappropriate activation in the brain will have 
deleterious consequences. Apoptotic death is involved in the pathogenesis of PD. 
 
 
Fig. 6. Summary of the biology of Il-12 (adapted from Trinchieri, 2003) 
6. Adaptive immunity and inflammation 
Adaptive immunity is involved in the elimination of pathogens during the later phase of 
infection, (i.e. after activation of the innate immune system) and is elicited by B and T 
lymphocytes, which utilize immunoglobulins and T cell receptors, respectively, as antigen 
receptors to recognize “non self” molecules (Figure 6). These receptors are generated 
through DNA rearrangement and respond to a wide range of potential antigens. Adaptive 
immunity is acquired after a longer period in later life. 
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Lymphocytes, B-cells and T-cells are capable of responding rapidly to these specific 
insults/pathogens when the insult is again encountered. This mechanism allows a small 
number of genes to generate a large number of different antigen receptors which are 
expressed on each individual lymphocyte. This information will be inherited in all of the 
progeny, which includes memory B cells and memory T cells to give long-lived specific 
immunity. B cells play an important role in the humoral immune response while T-cells are 
intimately involved in cell –mediated immune responses. B cells are involved in the creation 
of antibodies that circulate in the blood and lymph which is known as humoral immunity. 
There are five types of antibodies, IgA, IgD, IgE, IgG and IgM. Upon activation, B cells 
produce antigen specific antibodies which in conjunction with the expression of unique B 
cell receptor (BCR), allow the identification of specific antigens. 
6.1 CD8+ T lymphocytes and cytotoxicity 
Naive cytotoxic T cells are activated when their T-cell receptor (TCR) strongly interacts with a 
peptide-bound MHC class I molecule. This affinity will depend on the type and orientation of 
the antigen/MHC complex. Once activated, the cytotoxic T cell undergoes a process known as 
clonal expansion in which it gains functionality, and divides rapidly, to produce a donor army 
of “armed”-effector cells which can travel throughout the body in search of cells bearing that 
unique MHC Class I + peptide. CD8 refers to a transmembrane glycoprotein which is a co-
receptor for the T cell receptor. CD8 will bind to class I MHC protein.  
6.2 CD4+ lymphocytes 
CD4+ lymphocytes, ( helper T cells), are immune response mediators which play an 
important role in establishing and maximizing the capabilities of the adaptive immune 
response. These cells have no cytotoxic or phagocytic activity but orchestrate the immune 
response by directing other cells to perform these tasks. CD4+ T helper cells can be induced 
to differentiate to specific lineages according to the local cytokine milieu, towards T helper 
type 1 Th1, Th2, Th17 and regulatory T cell (Treg) phenotypes. 
Microglial activation is propagated by T-cell releasing interferon-. This will sensitise the 
microglia by upregulating the expression of various immunoregulatory molecules including 
CD40 on their cell surfaces. Activation of the Janus kinase/signal transducer and activator 
of transcription (JAK/STAT) signalling pathway plays a central role in this IFN- induced 
CD40 expression. Modulation of the JAK/STAT signalling pathway may suppress the 
microglial-mediated inflammation. 
7. Adaptive immunity in PD 
Extraneuronal nitrated -synuclein is able to cross the BBB to the CSF where it will activate 
antigen presenting cells, (reviewed by Kosloski et al., 2010), i.e. naïve T cells. With 
appropriate co-stimulatory signals these cells will diferentiate into Teffs that will expand 
into different effector cell subtypes, e.g. Th1 and Th17 cells (Reviewed by Kosloski et al., 
2010). Such cells will drive the disease processes towards a pro-inflammatory situation. Th1 
cells express IL-2, IFN- and TNFthatare pro-inflammatory and will activate microglia. 
Th17 also elicits a pro-inflammatory effect (Kosloski et al., 2010) and will also secrete 
granzyme B, a cytolytic enzyme (Kebir et al., 2007). Th2 effectors release IL-4, IL-5 and IL-13 
and support anti-inflammatory responses. In addition Th1, Th2 and Th17 help in the 
production of antibodies which specifically target modified proteins for their removal by 
microglia. Th1 and Th17 Teffs are synthesied in the periphery and traverse the BBB to the 
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inflammatory foci of the nigrostriatum and identify the N--synuclein/major 
histocompatibility complex II which are presented by the antigen presenting microglia. The 
induction of Teffs will drive the microglia and the innate immune responses. 
 
 
Fig. 7. Neurons express many ‘self defence’ proteins and receptors to prevent attack from 
microglia (adapted from Griffiths et al., 2010) 
T cell infiltration is present in the CNS tissue of PD. Nitrated -synuclein may activate 
peripheral leucocytes and mediate the adaptive immune system to potentiate mictoglial 
activation. Several changes in cellular and humoral immune reponses are reported to occur 
in the peripheral immune system of PD patients, although no clear demonstration of 
leucocyte involvement at the site of the neuronal damage has been reported (Brochard et al., 
2009). However McGeer et al., (1998) identified cytotoxic T cells in the SNc of one PD patient 
while Hunot et al (1999) showed a dramatic increase of IFN- positive cells in brains of PD 
patients indicating that T cells mobilisation could be involved in the nigrostriastal injury in 
PD. In one further study by Brochard et al., (2009), higher densities of CD8+ and CD4+ T cell 
were present post mortem in PD brains. This may indicate that there are changes in the 
function of the blood brain barrier and that peripheral cells are entering the brain 
parenchyma. In a recent study, (Castellani et al., 2011) identified a subunit of CD3, part of 
the T receptor complex (TRC) on mature T cells, in Lewy bodies in PD. This subunit of CD3 
has also been shown to be involved in dendritic outgrowth and synaptic formation thus 
raising the possibility that CD3 dysregulation as a pathogenic factor in PD. 
8. Anti-inflammatory systems to regulate microglia activation 
There are several anti-inflammatory systems that play a role in regulating microglia activation 
which include CD200/CD200 receptor, vitamin D receptor, peroxisome proliferator-activated 
receptors and soluble receptor for advanced glycation end products (Lue et al., 2020) 
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8.1 CD200/CD200 receptor 
CD200 is a highly glycosylated protein. Its expression is primarily located to neurons and 
oligodentrocytes in human brain although both astrocytes and brain endothelial cells also 
express CD200 (Koning et al., 2007: Walker et al., 2009)  With increasing age a loss of mRNA 
CD200 expression is reported in cells of rodents (Frank et al., 2006) which may also occur in 
humans. CD200R expression is found on many inflammatory cells which include 
macrophages, neutrophils, microglia, granulocytes, T lymphocytes, astrocytes and 
oligodentrocytes (Rijkers et al., 2008). The only known function for CD200 is to bind to 
CD200R. This ensures that the microglia remain in the resting state, Figure 8. The binding at 
the N-teminal of each of these molecules activates specific anti-inflammatory signalling 
pathways in CD200R expressing cells, thereby down regulating the pro-inflammatory 
response (Hatherley and Barclay, 2004). Loss of CD200, which is evident in PD brain regions 
where there is a loss of neurons, will induce an accelerated microglia response (Hoek et al., 
2000)  In addition, the activation of the extracellular signal-regulated kinase (ERK), c-Jun N-
terminal kinase (JNK) and p38 mitogen activated protein kinase (MAPK) pathways will be 
inhibited by such binding (Zhang et al., 2004).  Treatment of microglia and macrophages 
with IL-4 and IL-13 significantly increased expression of CD200R, in vitro. However 
expression of these cytokines was not generally detectable in brain (Walker et al., 2009). 
These anti-inflammatory cytokines bind to the same receptor complex and can activate the 
STST-6 transcription factor. Activation of STST-6 occurs in IL-4 stimulated human brain 
microglia which correlates with increased expression of CD200R. IL-4 exerts a powerful 
control over CD200 expression and hence modifies microglial activation. Therefore 
enhancing levels of IL-4 in the brain would be advantageous. Both statins and Vitamin D(3) 
will enhance IL-4 levels and thereby enhance an anti-inflammatory effect. 
8.2 Vitamin D receptor (VDR) 
Vitamin D3 plays a central role in immunity by a) modulating the production of several 
neurotrophins, (b) upregulating IL-4, and c) inhibiting the differentiation and survival of 
dendritic cells ( Fernandes de Abreu, et al., 2009). Deficiency of vitamin D3 maybe 
associated with increased CNS diseases including PD (reviewed by Annweiler et al., 2009). 
The cellular receptor for vitamin D3, the vitamin D3 receptor (VDR), (nuclear receptor 
subfamily, group 1, member 1 (NR111) and calcitriol receptor is a member of the nuclear 
receptor family of transcription factors. Upon activation by vitamin D, the VDR forms a 
heterodimer with the retinoid-X-receptors which binds to hormone responsive elements on 
DNA, which causes an increased expression or repression of specific genes. Indirect 
evidence has suggested that PD have lower serum vitamin D than age matched controls 
(Sato et al., 2005). In a longitudinal study of 3000 participants in Finland, higher vitamin D 
levels were associated with a reduced risk of PD (Knekt et al., 2010). 
8.3 Peroxisome proliferators activated receptors 
The peroxisome proliferator-activated receptors, PPARs, belong to a superfamily of nuclear 
hormone receptors (Figure 8). Their main function is to regulate glucose and lipid 
metabolism and their subsequent storage. However, they also play a key role in the 
regulation of immune and inflammatory responses. PPARs can stimulate gene expression 
through binding to peroxisome-proliferator response elements, which are present in the 
promoter regions of target genes.  The PPAR subfamily is comprised of three isoforms, 
PPAR-, PAR/ and PPAR-.  PPAR are activated by small lipophilic compounds and 
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form heterodimers with the retinoid receptor- (RXR) in the cytoplasm for full activation. 
Specific binding of PPAR onto DNA sequences leads to the activation of gene cascades 
involved in several biological processes (Reviewed by Chaturvedi and Beal, 2008). In the 
absence of ligands, PPAR and RXR heterodimers bind to co-repressor complexes and 
suppress gene transcription (Reviewed by Chaturvedi and Beal, 2008). PPARS also 
downgrade the production of MMPs, known activators of microglia and PPAR- agonists 
have been shown to be neuroprotective in a number of PD models.  
 
 
Fig. 8. Schematic representation of the PPAR signalling pathway (Adapted from Michalik et 
al., 2004) 
9. Role of iron in inflammation in PD 
There is an increased burden of iron, approximately 2 fold, compared to controls, in specific 
brain regions, the SNc and lateral globus pallidus of PD brains which will enhance oxidative 
stress (Gotz et al., 2004). H-ferritin rather than L-ferritin is present in the iron loaded SNc and 
lateral pallidus of PD brain (Dexter, et al., 1990) with large amounts of iron being sequestered 
into neuromelanin in dopaminergic neurons. Furthermore, since the SNc has a relatively high 
metabolic rate, with a high content of dopamine, neuromelanin, polyunsaturated fatty acids 
and iron, but low antioxidant protection, e.g. reduced glutathione (Sian et al., 1994) oxidative 
stress will be enhanced. Both reactive oxygen and nitrogen intermediates will contribute to the 
demise of the dopaminergic neurons, leading to the formation of lipid peroxidation products, 
as well as protein carbonyls and DNA damage (Alam et al., 1997). In addition, ROS, generated 
as a result of mitochondrial malfunction, will contribute to this toxicity. The etiology of this 
enhanced brain iron content may be attributable to a variety of factors which include changes 
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in iron release mechanisms across the blood brain barrier, BBB, or perhaps more likely, a mis-
regulation of iron homeostatic control in the SNc.  
The control of iron homeostasis within microglia remains undefined. It is of interest that 
both microglia and iron deposits co-accumulate at the site of damage in PD. Whether these 
accumulations are a cause or effect of the disease is currently unknown. In our recent study 
(Ward et al., 2007) mRNA was isolated from two regions of Parkinson’s brain, the SNc and 
the cortex, and the expression of a number of iron genes quantitated and compared with 
those from control post mortem material. A significant number of genes were specifically 
up-regulated in the substantia nigra in comparison to the cortex in the PD brains as well as 
controls, Table 2. Such up-regulation of both transferrin and transferrin receptor2 in other 
cell types is associated with iron deficiency, and inflammation, respectively. The high iron 
content of the SNc might have been expected to diminish IRP1 and IRP2 activity. However 
IRP-1 expression did not alter significantly whilst IRP2, which dominates post-
transcriptional regulation of brain iron metabolism was up-regulated. A previous study, 
(Faucheux et al., 2002) reported no alteration of IRP-1 in SNc of Parkinsonian brain. The 
increased mRNA expression of ferroportin in SN might indicate an elevated flux of iron 
from certain cell types within the SNc.  
 
 
Table 2. Activated microglia secrete a number of factors which include  cytokines, 
chemokines and receptors 
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10. Role of blood brain barrier in inflammation 
The exact role played by the blood brain barrier (BBB) in excluding and permitting various 
molecules to cross the membrane remains an enigma. In early studies, molecular size was 
considered to be an important factor. However later studies have identified that passive 
diffusion across the blood brain barrier is very slow and that various transporters, solute 
carriers, as well as transcytosis, play important roles in determining whether molecules 
traverse the BBB. Furthermore endothelial astrocytes and neurons which are in contact with 
the cells of the BBB will influence intra and intercellular signalling (Neuwelt et al., 2011). 
The function of the BBB may be altered by inflammation in the periphery with inflammatory 
mediators inducing a significant paracellular leak. Immune cells are able to penetrate BBB, 
either at the endothelial BBB or the epithelial blood-CSF barrier. Interaction of endothelial 
cells with extracellular matrix will induce cross talk with adjacent cells which are pre-
requisite for barrier function. For example 4-1integrin/VCAM-1 is involved in leucocyte 
interaction with BBB. Inflammation and generation of ROS and RNS can acutely disrupt 
BBB at tight junction. Stress related pathways target nuclear transcription factors to increase 
P-glycoprotein expression in blood capillaries. There is altered expression of p-glycoprotein 
at BBB in PD.  Therefore BBB function may contribute to neuro-inflammation via 
deregulated entry of antigen-specific T cells, via compromised removal of toxic products of 
neuronal damage and death and lead to disease progression via signalling of systemic 
inflammation. It remains unclear whether there is BBB leakage in PD patients. 
Polymorphism in the P-glycoprotein drug transporter MDR1 gene association and ABCB1 
gene encoding the P-glycoprotein may alter the properties of the BBB in PD patients 
(Reveiwed by Neuwelt et al., 2011). 
11. Inflammation in the periphery 
Possible biofluids which can be used in the search for pertinent PD biomarkers are the 
cerebrospinal fluid, plasma and urine. It would be advantageous clearly to identify markers 
which precede the degeneration of nigrostriatal dopaminergic neurons. For example it is 
known that an impaired sense of smell is prevalent prior to and during the clinical motor 
stages of PD. Odour discrimination performance strongly correlates with risk of future PD 
(Berendse and Ponsen, 2009). In addition reduced striatal dopamine transporter SPECT 
imaging was also identified in subjects, who later developed PD. Biomarkers which 
correlated with these early physical symptoms would be of paramount important for early 
therapeutic intervention. In a small study of 84 subjects, (Chen et al., 2008), plasma 
inflammatory biomarkers were assessed approximately 4 years before PD diagnosis, IL-6 
was associated with a greater risk of PD. Other inflammatory markers such as C-reactive 
protein, fibrinogen, and TNF- were not related with risk. In contrast, analysis of serum and 
cerebrospinal fluid from PD patients which have active and progressive PD, it was not 
surprising that increased levels of the inflammatory cytokines TNF, IL-1, IL-2, IL-4, IL-6 
and interferon  were observed (Bacia et al., 2009).  Similarly, increased oxidative damage is 
involved in the progression of PD and plasma levels of F(2)-Isoprostanes, 
hydroxyeicosatetraenoic acid products, 7 beta and 27-hydroxycholesterol, 7 ketocholesterol, 
F(4)-neuroprostanes and urinary 8-hydroxy-2’-deoxyguanosine were elevated in PD 
patients while plasma levels of phospholipase A(2) and platelet activating factor 
acetylhydrolase activities were lower (Seef et al., 2010). 
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CSF may be the most promising biological fluid since it is in closer contact with 
degenerating neurons. The assay of both alpha-synuclein and DJ-1 have been shown to be 
good biomarkers for PD but larger clinical trials as to their potential use are needed. 
Although some studies have advocated the assay of a pattern of inflammatory cytokines, 
further investigations are required to ascertain their specificity for PD.  
Plasma homocysteine was increased in PD patients (Obeid et al., 2009) while platelet levels 
of amyloid precursor proteins and alpha synuclein may be pertinent markers of 
methylation. In addition various polymorphisms have been identified in the genes of 
TNFand its receptoras well as IL-1 and IL-1 (Wahner et al., 2007)All of these studies 
have been on small numbers of PD patients. However other studies have not confirmed the 
associations of such polymorphisms with PD disease (Reviewed by Hirsch and Hunot, 2009) 
which may indicate that such polymorphisms are involved in susceptibility to the causative 
agent of PD. More importantly such polymorphisms may reflect the basal levels of the 
inflammatory status of an individual or reflect the ability of phagocytic cells to respond to 
an inflammatory stimulus. 
Various changes in antibodies have been identified in the serum of PD patients although 
these have not been confirmed in all studies (reviewed by Hirsch and Hunot, 2009). 
Increased numbers of circulating CD4+ bright and CD8+ dull lymphocytes are detectable in 
the serum of PD patients (Hisanaga et al., 2001). Since the counts of these lymphocytes 
increase after viral infection, this could indicate that viral infections contribute to the 
pathogenesis of PD. 
12. Therapeutic aspects 
There have been some discussions as to whether improvements in the ability of the immune 
system to respond to the inflammatory turmoil maybe of importance in preventing the 
progression of PD. Probiotics, are dietary supplements which contain beneficial bateria, 
(lactobacillus and bifidobacterium), or yeast. They are administered in different quantities to 
allow for colon colonization. They help by stimulating health promoting flora as well as 
suppressing pathogenic colonisation and disease. It is claimed that probiotics will 
strengthen the immune system to combat allergies, stress and possibly neurodegenerative 
diseases (Saraf et al., 2010). 
12.1 Anti-inflammatory agents 
Some epidemiological studies have indicated that people who regularly use anti-
inflammatory drugs have less risk of developing clinical PD (Chen et al 2003., Chen., 2005), 
although this has not been confirmed in other studies (Ton et al., 2006; Bornebroek et al., 
2007; Hancock et al., 2007). Anti-inflammatory drugs may retard the progression of the 
degeneration although it remains to be elucidated whether their use would be an additional 
therapy in diagnosed PD patients. Inhibition of inflammation is associated with reduced 
neuronal impairment in various PD models (Gao et al., 2003; Wu et al., 2003) as discussed 
below. 
Non-steroidal anti-inflammatory (NSAI) drugs act by inhibiting the enzyme cyclooxygenase 
COX-1 and COX-2. While aspirin will inhibit both COX-1 and COX-2, ibuprufen will inhibit 
COX-2 only. COX-2 is specifically involved in dopaminergic degeneration. COX-2 inhibitors 
have been demonstrated to specifically inhibit microglia activation. NSAI may be effective 
in decreasing the incidence of PD which has been associated with the COX-inhibiting effect 
www.intechopen.com
 Mechanisms in Parkinson’s Disease – Models and Treatments 
 
134 
of these compounds (Chen et al., 2005). Minocycline may be effective in delaying PD 
progression by suppressing the formation of IL-1 and the activation of NADPH-oxidase 
and iNOS which are potent activators of microglia (NINDS 2006; Couzin 2007). The 
presence of polymorphisms of pro-inflammatory genes such as COX-2 genes may provide a 
genetic predisposition to initiate microglial activation. 
12.2 Antioxidants 
Antioxidants may reduce the progression of the neurodegenerative process. Lipoic acid is a 
universal antioxidants. Lipoic acid in its reduced form dihrolipoic acid is active against ROS 
and will reduce oxidative stress. (De Araujo et al., 2011). However peripherally 
administered antioxidant will need to be targeted to specific regions of the brain where 
oxidative stress occurs. 
12.3 Vitamins and mineral 
Micronutrients such as the Vitamins A, B6, B12, C, D and E, folic acid as well as iron, zinc, 
copper and selenium, are involved in the synergy to support the protective properties of the 
immune system and most are also essential for antibody production (Maggini et al., 2007). 
Supplementation with these micronutrients may enhance immunity. 
12.4 Steroid hormones 
Steroid hormones, such as 17 beta oestradiol or progesterone protect against dopaminergic 
degeneration which may explain why woman are less affected by PD. In addition oestrogens 
may reduce inflammatory processes in the brain (Reviewed by Barcia et al., 2009) diminishing 
glial cell activation around dopaminergic neurons possibly mediated by differential expression 
of oestrogen receptors on glial cells and neurons (Reviewed by Barcia et al., 2009). 
12.5 Flavonoids 
Flavonoids, a group of phenolic phytochemicals are abundant in various spices, vegetables 
and fruit.  Several medicinal properties have been ascribed to flavonoids which include anti-
oxidants, anti-inflammatory and anti carcinogenic. Apigenin and its phase I metabolite, 
luteolin reduce CD40 and CD40L expression on dentritic cells and basophils. In our recent 
investigation of apigenin and luteolin in cultured microglia it was demonstrated that both of 
these compounds significantly reduced CD40 expression induced by IFN-.  This was 
paralleled by significant decreases in the release of pro-inflammatory cytokines IL-6 and 
TNF by microglia. Such changes were due to inactivation of STAT1 (Datla et al., 2001, 2007; 
Zbarsky et al., 2005). 
12.6 Taurine and taurine prodrugs 
In our recent studies we have shown that taurine has an anti-inflammatory action by 
stabilistaion of IkappaB in macrophages and microglia (Ward et al., 2011). This in turn will 
reduce NFkappaB translocation to the nucleus and will prevent the release of pro-inflammatory 
cytokines. In earlier animal studies the protective effect of taurine in the 6-hydroxy dopamine 
model was reported (Ward et al., 2006). In the later studies, prodrugs of taurine have been 
developed, notably ethane--sultam, which reduce microglial activation in the brain of an 
animal model of neurodegeneration (Ward, Della Corte, Dexter unpublished data). 
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12.7 Iron chelators 
The iron content of the SNc increases in the brains of PD patients and is associated with the 
progression of the inflammatory process. Hence, it’s chelation may prevent the progression of 
the disease. Two clinically used iron chelators, namely the hexadendate, deferrioxamine and 
the tridendate chelator deferasirox have been investigated for their efficacy to induce 
neuroprotection in the 6-hydroxy dopamine (6-OHDA) animal model of PD. Acute 
administration of desferrioxamine, 0.4 mM or desferasirox, 1 mM, via a microdialysis probe 
into the striatum immediately prior to a dose of 6-OHDA, prevented the generation of 
hydroxyl radicals, as well as reducing bio-available iron. Intraperitoneal injection of the iron 
chelators, desferasirox, 20 mg/kg or desferrioxamine, 30 mg/kg or deferriprone 10mg/kg, to 
the 6-OHDA rat model, significantly attenuated the loss of tyrosine hydroxylase positive cells 
as well as elevating dopamine content in the lesioned striatum (Dexter et al., 2010). Such 
results would confirm that the administration of these chelators show therapeutic efficacy and 
should be considered to be an additional therapy for the treatment of PD. Clinical trials of 
deferiprone are now underway in a group of drug-naïve PD patients. 
12.8 MMP-3 inhibitors 
The development of selective MMP-3 inhibitors has proved difficult. It is unlikely that 
relatively large peptide based inhibitors of MMP-3 would cross BBB. Doxycycline, a 
tetracycline derivative that crosses the BBB can down regulate cell stress induced MMP-3 
expression and release and can therefore attenuate apoptosis in dopaminergic neurons (Cho 
et al., 2009). Minocycline protection of neurones from a variety of insults may in part be due 
to down regulation of MMP-3. However early clinical trials in PD patients were stopped 
because of unwanted side effects (NINDS NET-PD Investigators 2008). Preliminary studies 
of ghrelin, glycitein and exendin-4 have also shown down regulation of MMP-3 expression 
(reviewed by Kim and Hwang, 2011). 
12.9 PPAR modifications 
Several non-steroidal anti-inflammatory drugs bind to PPAR- and PPAR-. thereby 
activating their receptors. PPAR regulate the transcriptional activity of several transcription 
factors which include NFkappaB, the signal transducer factor-1 (STAT) and the activating 
transcription factor-1, ATF-1 and ATF-4. PPAR function by competing with NFkappaB for 
binding to the overlapping series of co-activators, i.e. cAMP-response element-binding protein 
(CREB), and inhibiting the NFkB mediated inflammatory response. PPAR also directly 
interacts with p65/p50/IkBsuppressing the DNA binding activity of NFkB.  PPAR also 
inhibit NFkB and AP-1 signal-dependent transcriptional activation of inflammatory genes by 
transrepression (Reviewed by Chaturvedi and Beal, 2008). Modulation of iNOS and 
cyclooxygenase may also occur.  PPAR may play a role in improving mitochondrial function. 
The neuro-protective role of PPAR agonists have been evaluated in PD patients. Agonists such 
as pioglitazone and rosiglitazone, may be able to protect against oxidative stress, apoptosis 
and inflammation in CNS (Reviewd by Chaturvedi and Beal, 2008). 
13. Inflammation in animal models of PD 
Activation of microglia has been identified in the SNc and /or striatum in various animal 
models of PD, which include the MPTP and lipopolysaccharides models (reviewed by 
Marinova-Mutafchieva et al., 2009). In addition, in the medial forebrain bundle axotomised 
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model, brain activation of microglia precedes neuronal loss (Gao et al., 2003). In the 6-
hydroxy dopamine models significant microglia activation was evident 48h after it’s 
administration as well as NADPH- derived free radicals prior to dopamine cell death in the 
SNc.  In our recent studies unilateral injection of 6-OHDA into the medial forebrain bundle, 
activation of microglia occurred rapidly, which selectively adhered to degenerating axons 
dentrites and apoptotic dopamine neurons in the SNc after 7 days.(Dexter et al 2011). After 
this time, there was a progressive loss of tyrosine hydroxlase positive neurons. These results 
indicated that microglia activation precedes dopamine neuronal cell loss. Furthermore 
neurons undergoing degeneration may be removed prematurely by microglia phagocytosis. 
(Marinova-Mutafchieva et al., 2009). In vitro it has also been shown that the toxicity of LPS 
to immortalised dopaminergic neurons was evident only when microglia were present in 
the cell culture (Gao et al., 2003). These results clearly indicate that activated microglia play 
an important role in the early stage of the disease pathogenesis.  
This review has confirmed that in PD there is a persistent and progressive inflammation both 
in the periphery and brain which is caused by changes in both the innate and adaptive 
immune systems which fuel the degeneration. The factors involved in the initiation of this 
cycle remains unknown. Although therapeutic intervention may diminish such inflammatory 
pathways, the goal for future researchers will be to identify the cause of such perturbations.  
Only then will there be the opportunity to develop new drugs which will cure PD. 
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Parkinson's disease (PD) results primarily from the death of dopaminergic neurons in the substantia nigra.
Current PD medications treat symptoms; none halt or retard dopaminergic neuron degeneration. The main
obstacle to developing neuroprotective therapies is a limited understanding of the key molecular mechanisms
that provoke neurodegeneration. The discovery of PD genes has led to the hypothesis that misfolding of
proteins and dysfunction of the ubiquitin-proteasome pathway are pivotal to PD pathogenesis. Previously
implicated culprits in PD neurodegeneration, mitochondrial dysfunction, and oxidative stress may also act in
part by causing the accumulation of misfolded proteins, in addition to producing other deleterious events in
dopaminergic neurons. Neurotoxin-based models have been important in elucidating the molecular cascade of
cell death in dopaminergic neurons. PD models based on the manipulation of PD genes should prove valuable
in elucidating important aspects of the disease, such as selective vulnerability of substantia nigra dopaminergic
neurons to the degenerative process.
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